Oculus launches topical wound drug in China

Dermacyn is initially being sampled to hospitals in as many as 10 provinces in China for treatment of various acute and chronic wounds including ulcers, cuts, contusions and burns.

According to the company, Dermacyn is a topical formation based upon the Microcyn technology platform that is capable of producing a potent broad-spectrum antimicrobial designed to treat a wide range of pathogens, including viruses, fungi, spores and antibiotic-resistant strains of bacteria such as Methicillin-resistant Staphylococcus aureus and Vancomycin-resistant Enterococcus, all of which cause disease or inhibit the healing in both acute and chronic wounds.

In March 2008, the Chinese State Food and Drug Administration approved Microcyn technology for treatment of various acute and chronic wounds including ulcers, cuts, contusions and burns, allowing the Microcyn technology to be promoted as a moist environment for wounds and accelerating wound healing through the reduction of microorganisms in wounds.

Hoji Alimi, CEO and founder of Oculus, said: “The sampling of Dermacyn in hospitals across China marks an important milestone in the implementation of our commercial strategy.

“Our alliance with China National Bohai Pharmaceutical Group Corp (Sinopharm) along with an additional 20 sub-distributors provides a strong entry into a market with enormous potential, and positions Dermacyn as a high-quality, effective alternative to current treatments. Our commercial plans in China call for entry into the retail pharmacy market as well.”